Biotech

News

Veraxa says delayed US listing is back on track

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

News

ADC specialist Solve raises $120m, and other biofinancings

Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.

News

Sofinnova Partners raises €650m for early-stage biotechs

European life sciences venture capital company Sofinnova Partners has closed its latest fund, Sofinnova Capital XI, raising €650 million.

News

Medicxi raises €500m for latest biotech fund

Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+.

News

Braveheart, AAVantgarde rounds head recent biofinancings

Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

News

Electra banks $183m for sHLH drug, and other biofinancings

Our round-up of recent biotech financings includes a big round for Electra, with Hemab, Zag Bio, Elevara, Expedition, and Curve also adding new funds.

Veraxa says delayed US listing is back on track

ADC specialist Solve raises $120m, and other biofinancings

Sofinnova Partners raises €650m for early-stage biotechs

Medicxi raises €500m for latest biotech fund

Braveheart, AAVantgarde rounds head recent biofinancings

Electra banks $183m for sHLH drug, and other biofinancings

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Biotech

Editor's Picks